Table 1 Correlation between nuclear TIF1γ, cytoplasmic TGFβ1and SMAD4 expression with the clinico-pathologic parameters of breast cancer
Variable | TIF1γ low | TIF1γ high | Pa | TGFβ1 low | TGFβ1 high | Pa | SMAD4 low | SMAD4 high | Pa | |
|---|---|---|---|---|---|---|---|---|---|---|
No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |||||
143 (64.1) | 80 (35.9) | 142 (69.6) | 62 (30.4) | 70 (40.5) | 103 (59.5) | |||||
Age (Yr) | -Mean (± SD) | 59.4(±12) | 55.9(±13) | 0.048b | 57.6(±12) | 59.3(±14) | 0.37b | 56.5(±12) | 57.1 (±12) | 0.74b |
Age groups | - ≤50y | 37 (26) | 35 (44) | 0.006 | 44 (31) | 21 (34) | 0.68 | 22 (31) | 38 (37) | 0.46 |
- >50y | 106 (74) | 45 (56) | 98 (69) | 41 (66) | 48 (69) | 65 (63) | ||||
Side | -Right | 68 (48) | 37 (46) | 0.85 | 62 (44) | 28 (45) | 0.84 | 30 (43) | 51 (49) | 0.39 |
-Left | 75 (52) | 43 (54) | 80 (56) | 34 (55) | 40 (57) | 52 (51) | ||||
T. size | - ≤2 cm | 80 (56) | 35 (44) | 0.08 | 73 (51) | 30 (48) | 0.69 | 31 (44) | 51 (49) | 0.49 |
- >2 cm | 63 (44) | 45 (56) | 69 (49) | 32 (52) | 39 (56) | 52 (51) | ||||
LN met | -Negative | 85 (59) | 41 (51) | 0.24 | 79 (56) | 35 (57) | 0.91 | 36 (51) | 55 (53) | 0.79 |
-Positive | 58 (41) | 39 (49) | 63 (44) | 27 (44) | 34 (49) | 48 (47) | ||||
SBR grade | -Gr 1 | 39 (27) | 6 (7) | <0.001 | 30 (21) | 11 (18) | 0.82 | 5 (7) | 26 (25) | 0.004 |
-Gr 2 | 72 (50) | 30 (38) | 63 (44) | 30 (48) | 35 (50) | 50 (49) | ||||
-Gr 3 | 32 (23) | 44 (55) | 49 (35) | 21 (34) | 30 (43) | 27 (26) | ||||
ER status | -Negative | 13 (9) | 15 (19) | 0.035 | 24 (17) | 6 (10) | 0.17 | 13 (19) | 7 (7) | 0.02 |
-Positive | 129 (91) | 64 (81) | 116 (83) | 56 (90) | 56 (81) | 95 (93) | ||||
PR status | -Negative | 28 (20) | 22 (28) | 0.18 | 38 (27) | 11 (18) | 0.14 | 18 (26) | 21 (21) | 0.40 |
-Positive | 113 (80) | 57 (72) | 101 (73) | 51 (82) | 51 (74) | 81 (79) | ||||
Her 2 status | -Negative | 126 (91) | 69 (87) | 0.35 | 125 (91) | 54 (89) | 0.66 | 60 (90) | 90 (89) | 0.93 |
-Over-expressed | 12 (9) | 10 (13) | 13 (9) | 7 (11) | 7 (10) | 11 (11) | ||||
Breast cancer subtype | -Luminal | 127 (91) | 64 (81) | 0.12c | 114 (83) | 55 (90) | 0.31c | 54 (81) | 94 (93) | 0.05c |
-Her2 rich | 2 (1) | 3 (4) | 4 (3) | 2 (3) | 2 (3) | 1 (1) | ||||
-Basal | 11 (8) | 12 (15) | 20 (14) | 4 (7) | 11 (16) | 6 (6) | ||||
(Neo)/ Adjuv. Hormonal ttt | -Tamoxifen | 101 (89) | 54 (87) | 0.89c | 95 (92) | 44 (83) | 0.20c | 48 (89) | 75 (94) | 0.48c |
-AI | 4 (4) | 3 (5) | 3 (3) | 2 (4) | 1 (2) | 1 (1) | ||||
-Tamoxifen + AI | 8 (7) | 5 (8) | 5 (5) | 7 (13) | 5 (9) | 4 (5) | ||||
(Neo)/ Adjuv. chemotherapy | -Anthra. | 52 (85) | 40 (82) | 0.61 | 58 (76) | 25 (83) | 0.59 | 34 (74) | 44 (80) | 0.48c |
only | 9 (15) | 9 (18) | 16 (21) | 5 (17) | c | 11 (24) | 11 (20) | |||
-Anthra. + | 1 (2) | 0 (0) | ||||||||
Taxane | 0 (0) | 0 (0) | 2 (3) | 0 (0) | ||||||
-Others | ||||||||||